Protocol Ledger

NCT04459715 · Phase III · TERMINATED

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and

Interventional Phase III clinical trial protocol NCT04459715 sponsored by EMD Serono / Merck KGaA in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-08-07 Enrollment: 730 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04459715
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)730 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04459715
Protocol FieldVerified Registry Value
NCT IdentifierNCT04459715
Consolidated Lead SponsorEMD Serono / Merck KGaA
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment730 participants (ACTUAL)
Registered Start Date2020-08-07
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI